Stay updated on DLL3-Expressing Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the DLL3-Expressing Advanced Cancer Clinical Trial page.

Latest updates to the DLL3-Expressing Advanced Cancer Clinical Trial page
- Check6 days agoChange DetectedThe record now presents details for a Phase 1/2 study of gocatamig, alone or with other therapies, in advanced DLL3-expressing cancers. It includes participant eligibility, study sites, outcome measures, record history, and information about data sharing.SummaryDifference87%

- Check13 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision number also advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the usual study record content. This blocks access to the study details and navigation on that page.SummaryDifference23%

- Check62 days agoChange DetectedThe page’s revision label was updated from v3.6.6 to v3.7.0. This indicates a recent update to the page content or metadata.SummaryDifference0.0%

Stay in the know with updates to DLL3-Expressing Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DLL3-Expressing Advanced Cancer Clinical Trial page.